Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Zyvox® Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries

1 Oct 2007

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotic Resistance in Bacteria
Share to Antimicrobial Resistance in Staphylococcus
Share to Pneumonia and Respiratory Infections

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17908617
DOI: 10.1016/j.diagmicrobio.2007.06.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Zyvox® Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countriesPMID 17908617Read ↗

Zyvox(R) Annual Appraisal of Potency and Spectrum (ZAAPS) Program: report of linezolid activity over 9 years (2004-12)Semantic proximity Read ↗

ZAAPS programme results for 2016: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 42 countries.Semantic proximity Read ↗

Surveillance for linezolid resistance via the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): evolving resistance mechanisms with stable susceptibility rates.Semantic proximity Read ↗

ZAAPS Program results for 2015: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 32 countriesSemantic proximity Read ↗

ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countriesSemantic proximity Read ↗

Five-Year Summary of In Vitro Activity and Resistance Mechanisms of Linezolid against Clinically Important Gram-Positive Cocci in the United States from the LEADER Surveillance Program (2011 to 2015)Semantic proximity Read ↗

LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States.Semantic proximity Read ↗

Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms.Semantic proximity Read ↗

Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014).Semantic proximity Read ↗

Molecular Characteristics and Antimicrobial Resistance of Linezolid-Resistant Staphylococcus aureus in Osteoarticular Infections: A 11-Year Study From a Hospital in Xi’anSemantic proximity Read ↗

<i>In Vitro</i> efficacy comparison of linezolid, tedizolid, sutezolid and delpazolid against rapid growing Mycobacteria isolated in Beijing, ChinaSemantic proximity Read ↗

Research progress on the oxazolidinone drug linezolid resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.